INTELLIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
INTELLIA THERAPEUTICS, INC. (NTLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $7.60 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-02-22
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-12-31 was $1.00M, a 0.00% change year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-09-30 was $4.80M, a 242.86% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-06-30 was $800.00K, a 92.38% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-03-31 was $1.10M, a 96.31% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $7.60M, a 82.24% decline from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $42.80M, a 83.66% decline from fiscal 2021.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $262.00M, a 1190.64% increase from fiscal 2020.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $20.30M, a 782.61% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $5.80M derived: sum of 2 quarters · filed 2024-02-22 | $6.60M derived: sum of 3 quarters · filed 2024-02-22 | $7.60M 10-K · filed 2024-02-22 |
| 2023-09-30 | $4.80M 10-Q · filed 2023-11-09 | $5.60M derived: sum of 2 quarters · filed 2023-11-09 | $6.60M 10-Q · filed 2023-11-09 | $7.70M derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-06-30 | $800.00K 10-Q · filed 2023-08-03 | $1.90M 10-Q · filed 2023-08-03 | $2.90M derived: sum of 3 quarters · filed 2024-02-22 | $4.30M derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-03-31 | $1.10M 10-Q · filed 2023-05-04 | $2.10M derived: sum of 2 quarters · filed 2024-02-22 | $3.50M derived: sum of 3 quarters · filed 2024-02-22 | $14.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.40M derived: sum of 2 quarters · filed 2024-02-22 | $12.90M derived: sum of 3 quarters · filed 2024-02-22 | $42.80M 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.40M 10-Q · filed 2023-11-09 | $11.90M derived: sum of 2 quarters · filed 2023-11-09 | $41.80M 10-Q · filed 2023-11-09 | $47.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $10.50M 10-Q · filed 2023-08-03 | $40.40M 10-Q · filed 2023-08-03 | $46.50M derived: sum of 3 quarters · filed 2024-02-22 | $217.80M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $29.80M 10-Q · filed 2023-05-04 | $36.00M derived: sum of 2 quarters · filed 2024-02-22 | $207.30M derived: sum of 3 quarters · filed 2024-02-22 | $237.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $177.50M derived: sum of 2 quarters · filed 2024-02-22 | $207.20M derived: sum of 3 quarters · filed 2024-02-22 | $262.00M 10-K · filed 2024-02-22 |
| 2021-09-30 | $171.30M 10-Q · filed 2022-11-03 | $201.00M derived: sum of 2 quarters · filed 2022-11-03 | $255.80M 10-Q · filed 2022-11-03 | $274.40M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $29.70M 10-Q · filed 2022-08-04 | $84.50M 10-Q · filed 2022-08-04 | $103.10M derived: sum of 3 quarters · filed 2023-02-23 | $104.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $54.80M 10-Q · filed 2022-05-05 | $73.40M derived: sum of 2 quarters · filed 2023-02-23 | $74.30M derived: sum of 3 quarters · filed 2023-02-23 | $74.80M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $18.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $19.50M derived: sum of 2 quarters · filed 2023-02-23 | $20.00M derived: sum of 3 quarters · filed 2023-02-23 | $20.30M 10-K · filed 2023-02-23 |
| 2020-09-30 | $900.00K 10-Q · filed 2021-11-04 | $1.40M derived: sum of 2 quarters · filed 2021-11-04 | $1.70M 10-Q · filed 2021-11-04 | $2.40M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $500.00K 10-Q · filed 2021-08-05 | $800.00K 10-Q · filed 2021-08-05 | $1.50M derived: sum of 3 quarters · filed 2022-02-24 | $1.70M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $300.00K 10-Q · filed 2021-05-06 | $1.00M derived: sum of 2 quarters · filed 2022-02-24 | $1.20M derived: sum of 3 quarters · filed 2022-02-24 | $2.50M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $900.00K derived: sum of 2 quarters · filed 2022-02-24 | $2.20M derived: sum of 3 quarters · filed 2022-02-24 | $2.30M 10-K · filed 2022-02-24 |
| 2019-09-30 | $200.00K 10-Q · filed 2020-11-05 | $1.50M derived: sum of 2 quarters · filed 2020-11-05 | $1.60M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.30M 10-Q · filed 2020-08-06 | $1.50M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $100.00K 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $18.00M 10-K · filed 2021-02-26 | |||
| 2017-12-31 | $1.60M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |